<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04862884</url>
  </required_header>
  <id_info>
    <org_study_id>HRS4800-101</org_study_id>
    <nct_id>NCT04862884</nct_id>
  </id_info>
  <brief_title>A Trial to Evaluate the Safety and PK Profile of HRS4800 in Healthy Subjects</brief_title>
  <official_title>A Phase 1, Single Center, Randomized, Double-blind, Placebo-controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, on the Pharmacokinetics of HRS4800 in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted to evaluate the safety and PK profile of HRS4800 tablets after&#xD;
      single oral administration in different dose levels compared to placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 3, 2021</start_date>
  <completion_date type="Anticipated">September 24, 2021</completion_date>
  <primary_completion_date type="Anticipated">September 3, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>HRS4800 tablets single administration in healthy male</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants with Adverse Events (AEs)</measure>
    <time_frame>1-21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants with Hematology, Clinical Chemistry, Urinalysis Laboratory Abnormalities</measure>
    <time_frame>1-21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants with 12-lead electrocardiograms (ECG) Abnormalities</measure>
    <time_frame>1-21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants with Vital Sign and Physical Examinations Abnormalities</measure>
    <time_frame>1-21 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax) of HRS4800,</measure>
    <time_frame>1-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Attain Maximum Observed Plasma Concentration (Tmax) of HRS4800,</measure>
    <time_frame>1-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC[last]) of HRS4800,</measure>
    <time_frame>1-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUCinf) of HRS4800</measure>
    <time_frame>1-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Terminal Elimination Half-Life (t1/2) of HRS4800,</measure>
    <time_frame>1-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination Rate Constant (λz, or kel) of HRS4800,</measure>
    <time_frame>1-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent Volume of Distribution (VZ/F) During Terminal Phase of HRS4800</measure>
    <time_frame>1-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total HRS4800 of Cumulative Amount Excreted in Urine (Aeu)</measure>
    <time_frame>1-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total HRS4800 of Fraction of Dose Excreted in Urine (feu)</measure>
    <time_frame>1-6 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>HRS4800 tablets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HRS4800 tablets</intervention_name>
    <description>Drug: HRS4800 tablets Low-dose group, single oral administration&#xD;
Drug: HRS4800 tablets Low-medium dose group, single oral administration&#xD;
Drug: HRS4800 tablets medium -dose group, single oral administration&#xD;
Drug: HRS4800 tablets Medium and high dose group, single oral administration&#xD;
Drug: HRS4800 tablets High-dose group, single oral administration</description>
    <arm_group_label>HRS4800 tablets</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Drug: placebo Low-dose group, single oral administration&#xD;
Drug: placebo Low-medium dose group, single oral administration&#xD;
Drug: placebo medium -dose group, single oral administration&#xD;
Drug: placebo Medium and high dose group, single oral administration&#xD;
Drug: placebo High-dose group, single oral administration</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Able to understand the purposes and risks of the trial and comply with all study&#xD;
             procedures before entering the trial, and provide signed informed consent.&#xD;
&#xD;
          2. Male aged between 18 years and 55 years at screening, inclusive.&#xD;
&#xD;
          3. Total body weight ≥50 kg at screening, and body mass index (BMI) between 19.0 and 26.0&#xD;
             kg/m2, inclusive.&#xD;
&#xD;
          4. Agree to take contraceptive measures and promise not to donate sperm since signing the&#xD;
             informed consent form, to 3 months after the administration.&#xD;
&#xD;
          5. No clinically significant abnormalities in medical history, general physical&#xD;
             examination, vital signs, laboratory tests (hematology, urinalysis, blood chemistry,&#xD;
             coagulation function), and ECG, as determined by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of severe digestive system disease or having a digestive disease currently&#xD;
             within 3 months of screening or before first dosing, and may affect drug absorption or&#xD;
             have safety risks.&#xD;
&#xD;
          2. Severe infections, injuries or surgeries within 3 months of screening or before first&#xD;
             dosing, or plan to undergo any surgeries during the trial.&#xD;
&#xD;
          3. ALT, AST, ALP or total bilirubin level exceeds the upper limit of normal (ULN) during&#xD;
             screening/baseline visits.&#xD;
&#xD;
          4. Subject's supine systolic BP is ≥140 mmHg or &lt;90 mmHg; diastolic BP ≥90 mmHg or &lt;60&#xD;
             mmHg at screening or before first dosing.&#xD;
&#xD;
          5. Positive breath alcohol test after confirmation in a repeat test during&#xD;
             screening/baseline visits.&#xD;
&#xD;
          6. Positive drug screening tests,.&#xD;
&#xD;
          7. Whole blood donation or loss of more than 200 mL of blood within 1 month prior to&#xD;
             dosing; or blood donation or loss of more than 400 mL of blood within 3 months prior&#xD;
             to dosing; or received blood within 2 months prior to dosing.&#xD;
&#xD;
          8. History of allergy to the study drug or any component of it.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>li Yue</last_name>
    <phone>86-021-61623632</phone>
    <email>li.yue@hengrui.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Miaoyan Chen</last_name>
    <phone>86- 021-61623632</phone>
    <email>Miaoyan.chen@hengrui.com</email>
  </overall_contact_backup>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 19, 2021</study_first_submitted>
  <study_first_submitted_qc>April 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2021</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

